We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Pleiotrophin Stimulates Expansion of Cord Blood Stem Cell Cultures

By LabMedica International staff writers
Posted on 29 Mar 2010
Researchers have identified a growth factor that stimulates the expansion of stem cell cultures from cord blood and that may make populations of such cells useful for treatment of patients lacking the cellular machinery --due to chemotherapy or radiation treatment, for example--for production of blood cells.

Investigators at Duke University (Durham, NC, USA) worked with a growth factor called pleiotrophin. More...
This growth factor is known by several other names including Neurite Growth-promoting Factor 1 (NEGF1), Heparin Affin Regulatory Peptide (HARP), or Heparin Binding Growth associated molecule (HB-GAM). It is an 18-kDa molecular weight growth factor that has a high affinity for heparin. During embryonic and early postnatal development, pleiotrophin is expressed in the central and peripheral nervous system and also in several nonneural tissues, notably lung, kidney, gut, and bone.

In the current study, the investigators treated mouse bone marrow hematopoietic stem cells (HSCs) with pleiotrophin. They also treated cultures of human cord blood cells with the growth factor as well as administrating it in a systemic fashion to irradiated mice.

Results published in the March 21, 2010, online edition of the journal Nature Medicine revealed that pleiotrophin stimulated a ten-fold expansion of mouse bone marrow stem cells. Treatment of human cord blood cultures resulted in substantially increased severe combined immunodeficient (SCID)-repopulating cell counts as compared to input and cytokine-treated cultures. Systemic administration of pleiotrophin to irradiated mice caused a pronounced expansion of bone marrow stem and progenitor cells, indicating that pleiotrophin was a regenerative growth factor for HSCs. So far, there has been no evidence that use of pleiotrophin could trigger formation of cancer cells, since the investigators have not seen any evidence of cancer in mice up to six months after treatment with pleiotrophin.

"These results confirmed that pleiotrophin induces stem cell regeneration following injury,” said senior author Dr. John Chute, professor of cell biology at Duke University. "Perhaps more importantly, systemic treatment with pleiotrophin may have the potential to accelerate recovery of the blood and immune system in patients undergoing chemotherapy or radiotherapy. At this point, any progress we can make that helps us better understand which biological pathways are activated in stem cells in response to pleiotrophin will help move the discovery forward.”

Related Links:

Duke University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.